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Background: Aggressive Non-Hodgkin lymphomas (NHL) are a group of lymphomas derived from germinal centre
B cells which display a heterogeneous pattern of oncogenic pathway activation. We postulate that specific immune
response associated signalling, affecting gene transcription networks, may be associated with the activation of
different oncogenic pathways in aggressive Non-Hodgkin lymphomas (NHL).
Methodology: The B cell receptor (BCR), CD40, B-cell activating factor (BAFF)-receptors and Interleukin (IL) 21
receptor and Toll like receptor 4 (TLR4) were stimulated in human transformed germinal centre B cells by treatment
with anti IgM F(ab)2-fragments, CD40L, BAFF, IL21 and LPS respectively. The changes in gene expression following
the activation of Jak/STAT, NF-кB, MAPK, Ca2+ and PI3K signalling triggered by these stimuli was assessed using
microarray analysis. The expression of top 100 genes which had a change in gene expression following stimulation
was investigated in gene expression profiles of patients with Aggressive non-Hodgkin Lymphoma (NHL).
Results: αIgM stimulation led to the largest number of changes in gene expression, affecting overall 6596 genes.
While CD40L stimulation changed the expression of 1194 genes and IL21 stimulation affected 902 genes, only 283
and 129 genes were modulated by lipopolysaccharide or BAFF receptor stimulation, respectively. Interestingly,
genes associated with a Burkitt-like phenotype, such as MYC, BCL6 or LEF1, were affected by αIgM. Unique and
shared gene expression was delineated. NHL-patients were sorted according to their similarity in the expression of
TOP100 affected genes to stimulated transformed germinal centre B cells The αIgM gene module discriminated
individual DLBCL in a similar manner to CD40L or IL21 gene modules. DLBCLs with low module activation often
carry chromosomal MYC aberrations. DLBCLs with high module activation show strong expression of genes
involved in cell-cell communication, immune responses or negative feedback loops. Using chemical inhibitors for
selected kinases we show that mitogen activated protein kinase- and phosphoinositide 3 kinase-signalling are
dominantly involved in regulating genes included in the αIgM gene module.
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Conclusion: We provide an in vitro model system to investigate pathway activation in lymphomas. We defined the
extent to which different immune response associated pathways are responsible for differences in gene expression
which distinguish individual DLBCL cases. Our results support the view that tonic or constitutively active MAPK/ERK
pathways are an important part of oncogenic signalling in NHL. The experimental model can now be applied to
study the therapeutic potential of deregulated oncogenic pathways and to develop individual treatment strategies
for lymphoma patients.
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Aggressive Non-Hodgkin lymphomas (NHL) are a het-
erogeneous group of lymphomas derived from germinal
centre B cells. 30% of NHL patients do not respond to
treatment. Current criteria to distinguish individual NHL
subtypes such as morphology, immunophenotype, and
genetic abnormalities do not allow reliable subtype
categorization and prediction of treatment response for
NHL cases. The pathological mechanisms behind this
heterogeneity are poorly understood. Thus there is a
need of new and additional methods for stratifying NHL.
The purpose of our studies is to estimate the extent to
which distinct signal transduction pathways could be re-
sponsible for the differences in gene expression that distin-
guish individual lymphomas. We postulate that signals
associated with the immune response can resemble path-
ways activated in distinct NHL subtypes.
To gain closer insight into the relevance of distinct cell
signaling networks to NHL subtypes, we stimulated human
transformed germinal centre B cells with factors known to
modify B cell signalling, or which are involved in B cell
microenvironment or lymphoma pathogenesis. We discov-
ered that coherent gene expression patterns, related to dis-
tinct in vitro stimuli, characterize individual NHLs.
Exemplified by an αIgM stimulation we identified signal-
ling pathways dominantly involved in regulating this con-
sistent global gene expression pattern.
We provide an in vitro model system of pathways acti-
vated in transformed B cells which allows a better
understanding of the global expression changes observed
in particular lymphoma subgroups. This model can be
used in the future to study the therapeutic potential of
oncogenic pathway activation and to develop individual
treatment strategies for patients.
Background
Mature aggressive Non-Hodgkin lymphomas (NHL) are
a heterogeneous group of lymphomas most often
derived from B cells during the germinal centre B cell
reaction [1-3]. Approximately 30 percent of patients
with NHL classified as diffuse large B cell lymphoma
(DLBCL) do not respond to treatment [4,5]. The criteria
currently used to distinguish between Burkitt lymphoma(BL) and DLBCL, is based on differences in morphology,
immunophenotype, and genetic abnormalities. These are
not reliably reproducible and most importantly the
pathological mechanisms behind these criteria are poorly
understood [3]. NHL cells proliferate actively and retain
many of the immunophenotypic characteristics of germi-
nal centre B lymphocytes. However, they are monoclonal
tumour B cells, and display characteristic nonrandom
chromosomal abnormalities. Cellular genes thus can be
placed under the control of heterologous promoter or en-
hancer elements and may switch off cellular growth regula-
tion. In contrast, specific combinations of signals for short
or long term stimulation are provided to germinal centre B
(GC B) cells through externally derived signals obtained
from cells in the microenvironment [1,6].
In peripheral secondary lymphoid organs B cells en-
counter foreign antigens. Antigen-stimulated B cells can
in turn form germinal centres. In the microenvironment
of germinal centres B cells need to interact with other
cells, such as T cells, tingible body macrophages, follicu-
lar dendritic and reticular cells [1]. Signal transduction
pathways initiated through the BCR determine the fate
of B cells in dependence of BCR affinity to antigen, con-
comitant engagement of coreceptors and the differenti-
ation stage of B cells [7]. GC B cells undergo apoptosis
if not rescued through GC survival signals. However, un-
resolved chromosomal translocations and/or perman-
ently deregulated autocrine or paracrine stimulations
counteracting these processes can lead to transformation
of GC B cells [1]. Within the GC B cell reaction or
maintenance of mature B cells additional factors are
involved including IL21, CD40L (TNFSF5 / CD154) or
tumour necrosis factor superfamily member 13b (BAFF /
TNFSF13b / CD257) [2,4-6,8]. In addition, there is evi-
dence for an involvement of pattern recognition receptors
in these processes [8]. It is well know from different cell
systems that after treating cells with the mentioned stim-
uli a number of pathways are activated. This includes
IL21-mediated modulation of janus-kinase (Jak) and sig-
nal transducer and activator of transcription (STAT) or
mitogen activated kinases (MAPK)1/2 (Erk1/2) [8]. Fur-
thermore, canonical and non-canonical nuclear factor-кB
(NF-кB), MAPK8/9 (JNK1/2), MAPK14 (p38a) signalling
Table 1 Differential expression in human transformed
germinal centre B cells in response to B cell-specific
stimulations
α-IgM CD40L IL21 LPS BAFF
Upregulated genes 3039 689 463 114 69
Downregulated genes 3557 496 439 169 39
Total number of genes affected 6596 1194 902 283 129
BL2 cells stimulated through αIgM treatment, by CD40L, IL21, BAFF or LPS.
RNA was hybridized onto U133A 2.0 plus Arrays. Differentially expressed genes
between stimulated and control cells were identified using linear models as
implemented in the bioconductor package LIMMA [36]. False discovery rates
for lists of differentially expressed genes were calculated according to
Benjamini and Hochberg [38]. Genes were ranked according to their p-value
for differential expression from the microarray experiments (adj. P value≤ 0.05).
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BAFF, canonical NF-кB by LPS [8-12]. In addition
Ca2+, phosphoinositide 3 kinase (PI3K), Erk1/2, canon-
ical NF-кB, JNK1/2, p38a signalling can be initiated by
B cell receptor activation [2,13-16]. In addition, aber-
rant signalling caused by a defined set of mutations or
autocrine and paracrine loops for these pathways have
been reported to be important for B cell lymphoma ini-
tiation or maintenance [2,11,17-19].
Recent large-scale gene expression profiling of NHL
tumour samples revealed a molecular definition for BL,
by describing a specific signature. This signature was
used to model an index of ‘Burkitt-likeness’ (mBL-index)
and to distinguish BLs from DLBCLs [20,21]. A funda-
mental question from these studies is the extent to
which different pathways could be responsible for the
differences in gene expression that distinguish individual
DLBCL. We hypothesized that gene transcription net-
works affected by immune response associated signals
resemble oncogenic pathway activity in DLBCL.
So far two major molecular patterns for DLBCLs are
described: so called activated B cell (ABC) like lymphoma
and germinal centre B cell (GC B) like lymphoma. They
can be complemented by for example host response,
stromal or even NF-кB specific gene expression signa-
tures [22-25]. Recent combinations of in vitro cell inter-
ventions with systems biology allowed the prediction of
potential oncogenic pathways involved in B cell trans-
formation [26-28]. Furthermore, in vitro studies showed
that combined STAT3 and NF-кB pathway activities are
central to ABC-like lymphoma cells [22,29,30]. In
addition, there is evidence that aberrant Toll like recep-
tor (TLR) and BCR signalling may be involved affecting
PI3K and/or MAPK/Erk signalling in addition to NF-кB
[13,18,31,32]. These data are based mainly on interven-
tions of constitutively activated pathways by knockdown
experiments and mutational analysis [2,13,18].
To get more insight into cell signalling networks and
their presence in individual human NHL, we utilized
human transformed GC B cells. We demonstrate that
B cell specific stimuli can be used to identify gene ex-
pression changes. This allows a “switch“ in gene ex-
pression from a steady state level characteristic of BL
towards that of DLBCLs. Representative sets of genes
(gene modules) are used to describe individual lymph-
omas. DLBCLs are heterogeneous in the appearance of
the magnitude of their gene module activation ranging
between “off” and “on”. Our data support the view
that, for example, tonic and/or activated mitogen acti-
vated protein kinase- and phosphoinositide 3 kinase
pathway components are part of a signalling network
that distinguishes individual DLBCL. Furthermore, a
useful in vitro model system to test for individual
treatment strategies is offered.Results and discussion
Global gene expression changes in human transformed
germinal centre B cells stimulated with B cell specific
paracrine stimuli
In order to achieve global gene expression changes to
describe major pattern of gene expression and to identify
pathway activity in aggressive NHL we used as our
model system, the BL2 cell line, which is derived from
germinal centre B cells [33-35]. BL2 cells were stimu-
lated using CD40L, BAFF, IL21, αIgM F(ab)2 fragments
or lipopolysaccharide (LPS) as described in Material and
Methods section (Additional file 1: Supplementary Mate-
rials and Methods). These stimuli were chosen, because
they are well known mediators of signalling in B cells,
involved in GC B cell microenvironment and involved in
B cell lymphoma initiation or maintenance [2,11,17-19].
Following stimulation, we wanted to identify gene ex-
pression changes which reflect pathways involved in lig-
and specific signal transduction and pathways potentially
active in aggressive NHL. Time points of stimulations
were chosen to achieve a signal strong enough to be
detected as gene expression change at the whole genome
level. Probes of three independent biological experi-
ments were hybridized to U133 plus 2.0 microarrays.
Differentially expressed genes were identified using lin-
ear models as implemented in the Bioconductor package
LIMMA [36]. False discovery rates of differentially
expressed genes were calculated according to the Benja-
mini and Hochberg in a paired-test as described in the
Material and Methods section.
Genes with the greatest change in expression and
with an adjusted p value ≤ 0.05 in response to each
stimulus were chosen for further analysis (Table 1 and
Additional file 2: Table S1, Additional file 3: Table S2,
Additional file 4: Table S3, Additional file 5: Table S4,
Additional file 6: Table S5). The top 100 differentially
expressed genes are depicted as heatmaps in Figure 1.
To our knowledge the only comparable data set avail-
able is from human transformed germinal centre B cells
(Ramos) which were cultivated on a CD40L expressing
Figure 1 Identification of IL21, CD40L, αIgM, BAFF and LPS regulated genes in transformed human germinal centre B cells using
microarrays. BL2 cell were stimulated with αIgM F(ab)2 fragments (3 hrs) (A), IL21 (2 hrs) (B), CD40L (6 hrs) (C), LPS (6 hrs) (D) and BAFF (9 hrs)
(E). RNAs from these cells were used for gene expression profiling on Affymetrix HGU-133 plus 2.0 microarray chips. The heatmaps show the
most highly changed gene expression (TOP100) (adj. p-value≤ 0.05) in response to each stimulus. Each row in the heatmaps represents a gene
and each column represents a microarray sample. Yellow and blue indicate high and low expression, respectively. Control probes (left column)
are shown in comparison to stimulated probes (right column). Additional details are summarized within Table 3 and suppl. Tables 1–5.
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experimental conditions, BL2 cells showed similar gene
expression changes after exposure to recombinant
CD40L for 6 hours (Additional file 7: Figure S1). In con-
trast, global gene expression changes after B cell receptor
activation, for BAFF, LPS or IL21 stimulation have been
described using different microarray-platforms. Therefore,
a quantitative comparison is difficult. Furthermore, differ-
ent cell lines or leukocyte cell subsets from a different ori-
gin, for example splenic murine B cells or bursal chicken B
cells were analysed. A selection of available data is sum-
marized in Additional file 8: Supplemental 1.
Gene set enrichment analyses of global gene expression
changes in transformed germinal centre B cells
Molecular functions, biological processes, cellular com-
ponents and pathways affected by distinct stimuli were
characterized by gene ontology (GO) based gene set en-
richment analyses (Additional file 9: Supplemental 2).
αIgM activated genes are linked to MAP kinase activ-
ity, phosphatase activity and transmembrane transporteractivity. The biological processes affected can be sum-
marized as regulation of immune responses, MAP kinase
activity, and programmed cell death, regulation of meta-
bolic processes (glucose / carboxylic acid / organic acid/
amino acid transport) or cell cycle and stress responses.
IL21 activated genes are enriched for gene sets associated
with responses to virus and other organisms and cytokine
production including type I interferon biosynthetic pro-
cesses. Furthermore, as for αIgM activated genes, IL21
affected gene sets are involved in regulation of pro-
grammed cell death. The involvement of IL21 activated
genes on cytokine signalling could also explain its relation
to IкB kinase/NF-кB cascade and NF-кB import into nu-
cleus, gene sets characteristic for Toll like receptor path-
ways, Jak/STAT and chemokine signalling pathway, but
also pathways in cancer are enriched. IL21 suppressed
genes are characteristic for nucleotidyltransferase activity,
cytoskeletal protein or phospholipid binding thus affecting
cell shape, morphogenesis or chemotaxis.
BAFF activated genes are involved in metabolic
processes of amino acids and chromatin remodelling,
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metabolic process, protein amino acid acylation.
The CD40L mediated gene expression changes positively
affect MHC class I receptor activity and thus antigen pro-
cessing and presentation of peptide antigen, the regulation
of membrane potential, small GTPase mediated signal
transduction as well as metabolic processes. In contrast,
CD40L suppressed genes are involved in phospholipase ac-
tivity or negative regulation of transcription.
Gene expression changes in transformed germinal centre
B cells of selected microarray results and validation by
quantitative real-time PCR
Stimulation of BL2 cells led to changes in the expres-
sion of genes involved in cell-cell communications, in-
cluding changes in HLA, PECAM, CD1, CD86 or
members of the signalling lymphocyte activation mol-
ecule family (SLAMF). Interestingly, expression of the
HLA group of genes was positively regulated as a re-
sult of all stimulations. IL21 affects, for example
HLA-B, -C and -E expression. The greatest upregula-
tion was observed for HLA-DPA1, -DQA1 and -DQB1
following BAFF, CD40L and αIgM treatment. Further-
more, CIITA was activated by CD40L and αIgM. Expres-
sion of the ICAM1 gene, which encodes a protein involved
in cellular adhesion and costimulatory signalling and
leukocyte trans-endothelial migration, is activated by all
the stimuli used (Table 2 and Additional file 2: Table S1,
Additional file 3: Table S2, Additional file 4: Table S3,
Additional file 5: Table S4, Additional file 6: Table S5).
IL21- treatment has the highest impact on ICAM1 activa-
tion [39]. CD58, a ligand of CD2, is activated by CD40L
and αIgM treatment [40].
SLAMF-associated proteins are important immuno-
modulatory receptors with roles in cytotoxicity, humoral
immunity, autoimmunity, cell survival, lymphocyte de-
velopment, and cell adhesion [41]. Whereas SLAMF1, 3
and 7 are strongly upregulated by BCR crosslinking,
SLAMF6 is inhibited. This inhibition is most prominent
in response to αIgM. In contrast, CD40L treatment is
associated with a decreased SLAMF3 expression.
Defined elements of the chemokine system are specif-
ically affected: IL21 upregulates CCR7, CXCR5 and
CXCL10, CD40L modulates the expression of CCL5
(increased), CCL17 (increased), CXCR7 (decreased) and
CXCL10 (increased), whereas αIgM treatment affects
CCR7 (increased), CXCR7 (decreased) and CXCL10
(increased). The chemokine receptor CCR7, involved in
germinal centre B cell homing is affected by CD40L but
much stronger through αIgM [42]. CCR7 plays a pivotal
role in homing of tumour cells into lymphoma-
supporting niches in secondary lymphoid organs [43].
The chemokine CXCL10 is involved in chemotaxis for
monocytes and T lymphocytes and has been reported toplay an important role in the pathogenesis of tissue ne-
crosis and vascular damage [44].
The expression of the inhibitor of DNA binding 1
(ID1) is inhibited in response to IL21, CD40L, αIgM, BAFF
or LPS treatment. The Id proteins are inhibitors of the
basic-helix-loop-helix (bHLH) transcription factors [45]. In
the B cell lineage, the ID1 gene is usually expressed in pro-
B cells and down regulated during differentiation [46].
Interestingly, inhibitors of DNA binding 1, 3 or 4 are inhib-
ited by several stimulations. ID3 expression is activated by
αIgM, whereas the other stimuli are leading to an inhib-
ition of ID3. ID4 expression is not affected by IL21,
whereas in all other cases it is inhibited.
The expression of BCL6, which is a central GC B cell
reaction regulator, is inhibited in response to all stimuli
[47]. However, the greatest effect was seen following
treatment of cells with IL21 and αIgM. Furthermore,
BCL6 interacting proteins, BCOR or BCL11A are also
affected, by αIgM or CD40L treatment. Interestingly, this
BCL6 downregulation is accompanied by increased ex-
pression of CXCL10 comparable to that described by
Shaffer and colleagues [48]. In addition, IRF4 is upregu-
lated in response to all stimuli although for BAFF this
was not significant. Termination of the GC reaction
requires IRF4 as well as the transcriptional repressor
Blimp1. IRF4 acts as a crucial transcriptional ‘switch’ in
the generation of functionally competent plasma cells
[49]. However, BLIMP1 (PRDM1) is only affected by
IL21 (Additional file 3: Table S2) [50]. In addition,
LMO2 (LIM domain only 2) is activated by αIgM and
IL21, a factor which also plays a central and crucial role
in hematopoietic development and is highly conserved
[51]. HGAL (GCET2) acting in concert with for example
LMO2 or Bcl6 is suppressed by αIgM and CD40L treat-
ment [52]. Interestingly, the expression of both AICD
and RAG2 is inhibited by αIgM treatment.
Regarding the GO-analysis, genes involved in pro-
grammed cell death mainly affected by CD40L, αIgM
and to some extend also by IL21. Thus, we observed
changes in gene expression for example for BCL2,
BCL2A1 (BFL), BCL2L1 (BclXl), BCL2L11 (BIM),
BCL2L12, CFLAR, FAS or MCL1).
Gene expression changes in response to IL21, CD40L,
αIgM, BAFF and LPS were also measured by quantita-
tive real time PCR (Figure 2). As exemplified for
ICAM1, CD58, CCR7, CXCL10, ID1, BCL6, MYC,
RGS1, DUSPs and SLAMF members (Figure 2A-O) an
overall good agreement of qRT-PCR data with the
microarray data is observed.
Elements of the Wnt pathway are affected by in vitro
interventions
LEF1 was recently defined as a signature gene in defining
the index of Burkitt-likeness [20]. Thus, we investigated
Table 2 Gene expression changes in human transformed germinal centre B cells of selected microarray results
Gene symbol log2FC Suggested function or pathway
a-IgM CD40L IL21 BAFF LPS
CIITA 0,79 0,81 - - - Antigen presentation
HLA-B 0,32 0,83 0,26 0,57 0,51 Antigen presentation
HLA-C 0,34 0,71 0,28 0,52 0,5 Antigen presentation
HLA-DPA1 0,81 0,62 - - 0,84 Antigen presentation
HLA-DQA1 1,54 1,13 - 0,75 0,74 Antigen presentation
HLA-DQB1 2,2 0,99 - 0,77 0,72 Antigen presentation
HLA-E - - 0,64 - 0,54 Antigen presentation
BCL11A −0,82 - −0,34 - - apoptosis
BCL2 1,63 - - - - apoptosis
BCL2A1 4,3 - 1,93 - - apoptosis
BCL2L1 0,41 - 0,89 - - apoptosis
BCL2L11 0,43 - 0,44 - - apoptosis
BCL2L12, 0,34 - - - - apoptosis
CFLAR −0,43 0,74 0,54 0,45 - apoptosis
FAS 0,91 0,83 0,89 - - apoptosis
MCL1 0,57 - 1,01 - - apoptosis
CD1C 2,67 - - - - Cell-cell communication, immune response
CD58 1,94 1,52 - - 0,84 Cell-cell communication, immune response
CD86 1,16 −0,54 - - −0,34 Cell-cell communication, immune response
ICAM1 0,75 1,01 2,91 0,65 0,48 Cell adhesion
PECAM −0,31 −0,56 - - −4,9 Cell adhesion
SLAMF1 0,47 - - - - Cell-cell communication, immune response
SLAMF3 4,14 −0,36 - - −0,42 Cell-cell communication, immune response
SLAMF6 −1,1 −0,48 −0,65 - - Cell-cell communication, immune response
SLAMF7 2,07 - - - - Cell-cell communication, immune response
DUSP10 2,17 - 0,89 - - Phosphatase activity, Negative regulation of MAPK
DUSP2 2,99 - 1,09 - - Phosphatase activity, Negative regulation of MAPK
DUSP22 0,74 0,98 - - 0,53 Phosphatase activity, Negative regulation of MAPK
RGS1 5,5 - - - - Negative regulation of G-protein couppled receptors
CXCL10 - 0,4 1,63 - - chemokine
CCR7 3,6 - 0,57 - - Chemokine receptor
CXCR5 0,38 - 1,14 - - Chemokine receptor
BCL6 −2,03 −0,48 −1,94 - - Gene regulation, B cell differentiation
BCOR −0,69 - - - - Gene regulation
GCET2 −0,95 −0,45 - - - Gene regulation, B cell differentiation
ID1 −2,12 −2,04 −1,53 −2,1 −1,9 Gene regulation
ID2 0,74 - - - - Gene regulation
ID3 0,72 −1 −1,58 −0,56 −0,82 Gene regulation
ID4 −2,71 −0,83 −0,78 0,91 −0,79 Gene regulation
IRF4 1,53 0,46 2,14 - 0,58 Gene regulation, B cell differentiation
LMO2 1,45 - 0,53 - - Gene regulation, B cell differentiation
PRDM1 - - 0,47 - - Gene regulation, B cell differentiation
AICD −0,76 −0,34 0,82 Somatic hypermutation and class switch recombination
AXIN1 0,4 - - - - Wnt pathway
BCL9 −0,44 - - - - Wnt pathway
DVL1 −0,3 - - - - Wnt pathway
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Table 2 Gene expression changes in human transformed germinal centre B cells of selected microarray results
(Continued)
FLI1 −0,6 - - - - Wnt pathway
FRAT1 −0,37 - - - - Wnt pathway
FRAT2 −0,96 - - - - Wnt pathway
FRZB −0,72 −0,39 - - - Wnt pathway
FZD2 −0,56 −0,29 - - −0,28 Wnt pathway
FZD3 −0,81 - - - - Wnt pathway
FZD6 0,32 - −0,3 - - Wnt pathway
Kremen2 - 0,35 - - - Wnt pathway
LEF1 −0,85 - - - −0,37 Gene regulation, Wnt pathway
Myc −0,72 - - - - Gene regulation, Wnt pathway
PYGO1 1,13 - - - - Wnt pathway
RAG2 −0,55 VDJ-recombination
TCF7 - 0,44 - - - Wnt pathway
TLE3 −0,66 −0,48 - - −0,35 Wnt pathway
WNT10 −1,37 - - - - Wnt pathway
WNT3 0,4 - - - - Wnt pathway
WNT5a −0,72 0,93 - - - Wnt pathway
WNT5B - 0,5 - - - Wnt pathway
A specific regulation of genes encoding for proteins involved in cellular adhesion and costimulatory signalling, cell-cell communications or antigen presentation
and immunomodulation, cytotoxicity, humoral immunity, autoimmunity, cell survival, lymphocyte development, and cell adhesion, chemokine pathways,
apoptosis or Wnt-signaling and GC B cell reaction regulation is revealed. Data are presented as log2FC from one probe set. Additional details are found in
Additional file 2: Table S1, Additional file 3: Table S2, Additional file 4: Table S3, Additional file 5: Table S4, Additional file 6: Table S5.
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Interestingly, αIgM stimulation led to reduced LEF1 ex-
pression (Figure 2P). The same was observed for BCL9.
PYGO1 expression was elevated in response to BCR activa-
tion. This was verified by qRT-PCR analysis. Comparable
to the stimulation effect on LEF1 expression, we verified
the dominant effect of αIgM treatment on BCL9 (down)
and PYGO1 (up) (Figure 2Q, R). Furthermore, AXIN1,
FZD2, 3, 6, FRAT1, 2 or DVL1, FLI1, TLE3, FRZB, WNT3,
5A, 10 were changed to a lesser extent by αIgM. This is an
important observation because Wnt5a produced by fol-
licular dendritic cells affects the B cell differentiation
program of germinal centre B cells [53]. The expression
of FZD6 and WNT5a are modulated by IL21 and TLE3
by LPS. In addition, CD40L modulates the expression of
FRZB, KREMEN2, TCF7, TLE3 and WNT5A (Table 2).
Therefore, we conclude that αIgM stimulation affects
major signature genes such as MYC and LEF1 defining
the index of Burkitt-likeness [20].
IL21, CD40L, αIgM, BAFF and LPS affected gene
expression changes: similarity and uniqueness
In order to describe similarities in gene expression the
global responses to the stimuli were analysed by the
Ordered List approach (Figure 3) [54]. In this approach,
genes were ranked according to their fold change in re-
sponse to respective stimulation. Pairwise comparisons
of top and bottom ranks of lists representing IL21,CD40L, αIgM, BAFF and LPS responses were plotted.
We observed a high overlap of genes responding in the
same manner for each pairwise comparison (p < 0.005).
This can be seen in Figure 3 by the difference between
the blue line, representing the number of overlapping
genes at the corresponding position of the gene lists
given and the orange area giving the expected size of a
random overlap. The gene lists are also compared in
reversed order represented by the green line. The genes
are summarized within the supplementary information
(Additional file 10: Table S6, Additional file 11: Table S7,
Additional file 12: Table S8, Additional file 13: Table S9,
Additional file 14: Table S10, Additional file 15: Table
S11, Additional file 16: Table S12, Additional file 17:
Table S13, Additional file 18: Table S14, Additional file 19:
Table S15). The strongest overlap was observed for IL21
and αIgM. This is somehow surprising since it was sug-
gested that the shared NFкB driven gene expression
changes mediated by LPS, CD40L, αIgM or BAFF would
be dominant in defining the major pattern of gene expres-
sion changes. However, the strong overlap of IL21 with
αIgM is also reflected in the GO analysis, showing that
IL21 and αIgM gene expression changes are enriched for
positive regulation of the IкB kinase/NF-кB cascade, RNA
metabolic processes or immune system processes but also
DNA-repair (Additional file 20: Supplemental 3). The
shared functions of CD40L and αIgM affected genes are
for example characterized by immune response, antigen
Figure 2 Expression of a selection of genes after stimulation in transformed human germinal centre B cells as detected by qRT-PCR.
BL2 cells were stimulated as described in Figure 2. One representative experiment out of two is shown. All samples were analysed in triplicates.
Expression of ICAM1, CD58, CCR7, CXCL10, ID1, BCL6, MYC, RGS1, DUSP2, -10, -5, -22, SLAMF −3, -7, -6, LEF1, BCL9, PYGO1 is shown as 2-ΔΔCT or ΔCT
values, relative to abl housekeeper expression and compared to unstimulated control. CXCL10 (D), RGS1 (H), DUSP5 (K) and SLAMF7 (N) show no
detectable expression in unstimulated cells (basal ΔCt > 10). Therefore, expression is depicted as ΔCt values. N.E. = Not Expressed.
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Figure 3 Overlap in global gene expression of IL-21, CD40L, αIgM, BAFF and LPS affected genes. BL2 cells were stimulated and data were
processed as described in the text. The overlaps of differentially expressed gene lists at both ends were compared using the “Ordered List package” [55].
Genes affected by the stimuli assigned on top of each plot are compared. The gene lists are compared in the same (blue line) or reversed order (green
line). The y-axis gives the size of the overlap in the number of genes of the top n-genes (x-axis) in both gene lists. The orange line gives the expected
size of a random overlap, and the vertical orange lines indicate 95% probability intervals of random overlaps. All overlaps show a high statistical
significance (α< 0.005). Additional details are summarized within Additional file 10: Table S6, Additional file 11: Table S7, Additional file 12: Table S8,
Additional file 13: Table S9, Additional file 14: Table S10, Additional file 15: Table S11, Additional file 16: Table S12, Additional file 17: Table S13, Additional
file 18: Table S14, Additional file 19: Table S15.
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activation, BMP signalling pathway and phosphate meta-
bolic processes.
In addition, we describe genes that are specifically
affected only by one of the utilized stimuli (uniqueness)
(Additional file 21: Table S16). Interestingly, those genes
which are dominantly affected by αIgM treatment are
part of biological processes such as nucleic acid binding,
PI3K regulator activity, regulation of cell cycle or meta-
bolic processes, Wnt receptor signalling pathways and
response to hypoxia (Additional file 22: Supplemental 4).
Therefore, our data now provide a comprehensive col-
lection of gene expression changes induced by different
physiological stimuli. These data sets can be used for a
better understanding of gene expression changes in B
cell signalling and lymphoma as we will show below. An
in vitro model system will be tested to investigate path-
way activations in individual DLBCL.
Coherent gene expression of αIgM affected genes
characterizes individual NHL
To further underpin the functional relevance of the gene
expression changes observed following treatment with the
stimuli, we investigated whether the change in expressionof these genes is comparable to primary NHL. Two inde-
pendent patient cohorts were included. The gene expres-
sion profile from 219 primary tumour samples described
by Hummel et al. (MMML1 cohort) and 99 published by
Dave et al. (LLMPP cohort) were compared to the gene ex-
pression changes described above [20,21]. The genes were
summarized in Table 3. In some cases less genes were used
because they were missing on the microarrays used for
lymphoma gene expression analysis.
αIgM driven gene expression changes had the greatest
absolute fold changes therefore we started with these. The
expression levels of a list of 100 genes with a FDR < 0.1
were examined in clinical lymphoma samples. Their joint
expression was estimated using a standard additive model
fitted by Tuckey’s median polish procedure. These gene
groups are further referred to as gene modules. The αIgM
gene module can be used to differentiate BLs from
DLBCLs shown in a heatmap (Figure 4A) [20]. On top of
the heatmap are labels for the molecular classification
(index of Burkitt-likeness, molecular ABC/GCB-classifica-
tion) and the presence of a chromosomal translocation of
MYC. Patients from the MMML1 cohort are sorted
according to their increase in the expression of genes from
the gene module. On the right part of the heatmap
Table 3 Most prominent altered genes after in vitro interventions of human transformed germinal centre B cells
investigated in gene expression profiles of primary samples of aggressive Non-Hodgkin Lymphoma
BAFF CD40L anti-IgM IL21 LPS
Gene symbols log2FC Gene symbols log2FC Gene symbols log2FC Gene symbols log2FC Gene symbols log2FC
1 ID1 −2,07 ID1 −2,007 CYP26A1 −2,752 BCL6 −1,904 ID1 −1,9
2 ID4 −0,92 C3orf37 −1,432 ID4 −2,687 SOX2* −1,805 RGS18* −0,853
3 BNIP3 −0,79 SMAD1* −1,182 BEST3* −2,41 DNAJB4 −1,589 C3orf37 −0,85
4 TXNIP −0,74 DEPTOR −1,159 IL7R* −2,399 ID3 −1,534 DDIT4 −0,83
5 BNIP3L −0,72 CAB39L −1,086 BMP7 −2,373 DDIT4 −1,514 ID3 −0,811
6 PFKFB4* −0,71 CD83 −1,017 SOX4 −2,343 ID1 −1,493 METTL7A −0,8
7 GPER −0,68 METTL7A −1,005 TNFSF8* −2,264 RGCC −1,239 CAB39L* −0,799
8 PNOC −0,67 ANKRD36BP2* −0,983 RNF144B* −2,213 IL7R −1,152 TXNIP −0,786
9 RGS18* −0,66 ID3 −0,983 DNAJB4 −2,156 HEY2* −1,136 BNIP3 −0,776
10 P4HA1 −0,654 ENPP3* −0,937 ID1 −2,093 VEGFA −1,115 ID4 −0,776
11 CCNG2 −0,635 IRF8 −0,924 BCL6 −2,037 GADD45A −0,982 CCNG2 −0,721
12 HILPDA −0,631 RGS18* −0,919 RHOH −2,005 CYTIP −0,93 PFKFB4* −0,709
13 ID2 −0,585 FAM167A* −0,909 RGCC −1,946 PCDH9 −0,914 KDM3A −0,69
14 SAMD13* −0,582 AICDA −0,864 NCKAP1 −1,857 CCNG2 −0,889 HILPDA* −0,678
15 CD24 −0,578 GPER −0,852 IKZF1* −1,845 TXNIP −0,872 FAM167A* −0,673
16 ID3 −0,564 ID4 −0,835 HEY2* −1,761 BICD2 −0,868 PTPRC −0,665
17 C3orf37 −0,56 PDZRN4 −0,809 PCDH9 −1,751 RGS18* −0,861 STAT2* −0,649
18 GPR18 −0,541 BNIP3 −0,785 SOX2* −1,723 ANKRD37* −0,852 SAMD13* −0,631
19 ALDOC −0,516 VEGFA −0,777 MYCT1* −1,716 TRIM8 −0,836 ENPP3* −0,609
20 BBOX1 −0,516 TP53INP1* −0,776 RGS18* −1,715 KIAA0907 −0,786 SMAD1* −0,593
21 CD83 −0,509 PTPRC −0,77 SMAD1 −1,679 NEDD9 0,787 P4HA1 −0,593
22 POLD4 −0,494 RASSF6* −0,767 MLLT3 −1,656 RELB 0,79 VEGFA −0,592
23 HBP1 −0,484 CCNG2 −0,761 KIF20A −1,631 PAPD5* 0,791 KLRC3 −0,591
24 FAM167A* −0,476 CLEC2B −0,74 FAM214A* −1,612 ZNFX1* 0,794 GPER −0,588
25 EVI2A −0,476 BMP7 −0,735 BCL2 1,618 B3GNT2* 0,797 ZNF385B* −0,588
26 TP53INP1* −0,474 TLR1 −0,732 PSAT1* 1,62 HIF1A 0,814 TP53INP1* −0,583
27 YPEL5 −0,467 SATB1 −0,731 LOC285628* 1,637 KIF26B 0,814 UBE2H* −0,581
28 TRIM22 −0,464 BTG2 −0,726 FAIM3 1,641 MMD 0,82 TRIM22 −0,571
29 TLR1 −0,463 PCDH9 −0,725 MAP2K3 1,644 AICDA* 0,822 PIK3C2B −0,571
30 CLEC2B −0,463 PRKACB −0,724 PPP1R15A 1,662 EPSTI1* 0,837 STAP1 −0,564
31 HLA-C 0,457 GPM6A −0,721 FAM208B 1,674 RAB11FIP1 0,844 BNIP3L −0,558
32 ACTR3* 0,46 STAT2* −0,72 SIAH2 1,676 RAB30 0,845 MYBL1 −0,556
33 NAF1* 0,46 CLIP2 0,721 HIVEP3* 1,679 SIN3A* 0,847 GPM6A −0,549
34 PSMD12 0,461 ARHGAP17 0,727 METRNL* 1,711 PLEK 0,854 ANKRD37* −0,548
35 NUDT5* 0,461 CFLAR 0,74 HERPUD1 1,727 IFITM1 0,863 SPG11 −0,537
36 TESC 0,463 FYTTD1* 0,743 KLF10 1,749 PRDM2 0,885 NARF −0,536
37 CCAR1* 0,464 HLA-DMB 0,747 LTA 1,753 DUSP10 0,888 ABCA1 −0,531
38 ANKRD33B* 0,465 MTMR10* 0,749 GPR18 1,769 FAM100B* 0,892 SEC14L1 −0,531
39 RILPL2* 0,466 HLA-F 0,754 IFRD1 1,777 FAS 0,894 IL7R −0,522
40 PLCB1 0,467 PLEK 0,757 CD274* 1,785 IL7 0,896 H1FX −0,52
41 NFKBIE 0,47 PPP1R9B* 0,759 SLC3A2 1,79 CD69 0,921 ASF1A −0,511
42 DDX21 0,47 TESC 0,764 HSPA5 1,8 B4GALT1* 0,923 GLCCI1* −0,509
43 TAPBP 0,471 IGLL1 0,765 ATF3 1,834 BCL2L1 0,924 EVI2A −0,508
44 RBBP6 0,474 SNX20* 0,765 DENND4A 1,848 CD40 0,934 VGLL4 −0,507
45 SOGA2 0,474 CREM* 0,77 ARHGAP25 1,849 TET3* 0,951 PRKACB −0,503
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Table 3 Most prominent altered genes after in vitro interventions of human transformed germinal centre B cells
investigated in gene expression profiles of primary samples of aggressive Non-Hodgkin Lymphoma (Continued)
46 HINT1* 0,474 IKBKE 0,782 TOR3A 1,85 SOCS1 0,962 LRP4 −0,499
47 SRRM1 0,475 FAS 0,788 IRF2BP2* 1,868 NFKBID* 0,983 PLCXD1 −0,498
48 PHACTR4 0,475 CIITA 0,788 SLC30A1 1,886 SRSF5 0,996 CLEC2B −0,497
49 AK3* 0,476 TAP1 0,789 TNF 1,905 MASTL* 1,011 LOC440864* −0,494
50 KPNB1 0,477 NOTCH2NL* 0,797 CTH 1,91 TLR7 1,036 SLC44A1* −0,493
51 GTF2H2B* 0,477 RFX5 0,806 APOBEC3B 1,928 MCL1 1,04 TSPAN11* −0,484
52 TAF1D 0,477 FDXR 0,81 NFKB1 1,94 PIM2 1,06 BTN2A2 0,488
53 CSF2RB 0,479 NFKBIE 0,827 CD58 1,946 IER2 1,067 NFKBIE 0,493
54 MYBBP1A 0,481 MIR155HG* 0,829 NFKBIE 1,958 ZFP36L1 1,072 HLA-C 0,495
55 YY1* 0,483 LOXL2 0,829 NAB2 1,984 IFIT2* 1,072 LSS 0,502
56 FLVCR1* 0,488 HLA-B 0,831 JUND 2,024 SNX11 1,078 FDXR 0,502
57 NAA16 0,49 VAV2* 0,832 ARL4C 2,026 TAP1 1,086 KLHDC5* 0,505
58 SRRT 0,491 ZNF385C* 0,836 UPP1 2,029 JUNB 1,088 HLA-B 0,511
59 TNRC6A* 0,493 RASSF2 0,841 CDKN1A 2,033 LRRC32 1,1 CCDC28B 0,514
60 FNBP1 0,494 HLA-E 0,843 FAM100B* 2,059 NA 1,101 HLA-DMB 0,517
61 CIZ1 0,495 BIRC3 0,845 MDFIC 2,091 MARCKS 1,108 CUX2 0,519
62 TOMM40 0,495 ANKRD33B* 0,847 IER2 2,137 DUSP2 1,134 DUSP22* 0,523
63 TBC1D24* 0,498 ANXA7 0,85 DUSP10 2,144 NUDT4 1,139 RPS6KA1 0,527
64 ILF3 0,498 HVCN1* 0,85 FAM102A 2,198 CXCR5 1,155 HLA-DOA* 0,527
65 NFKB2 0,501 EPB41L4B* 0,86 RAB8B* 2,198 IER5 1,155 SYNCRIP 0,528
66 TFDP1* 0,505 PIK3CD 0,864 PTGER4 2,204 BCL3 1,16 ZNF385C* 0,533
67 ZNF385C* 0,508 LAT2 0,871 HLA-DQB1 2,206 SAMSN1 1,18 DENND4A 0,535
68 LYAR* 0,508 HCP5 0,884 ARAP2 2,214 NFKBIZ* 1,2 PDLIM3* 0,535
69 BIRC3 0,508 HLA-DOA* 0,894 SLC7A11 2,215 IL2RA 1,211 FYTTD1* 0,536
70 LRP8 0,513 SYNGR2 0,901 MIR155HG* 2,249 PARP9* 1,212 ELL2* 0,537
71 CCDC28B 0,514 ALCAM 0,905 CD69 2,278 USP18 1,229 HLA-E 0,539
72 C8orf12* 0,514 WNT5A 0,916 TSC22D3 2,287 MAP3K8 1,333 IRF2BP2* 0,539
73 HLA-B 0,519 RUNX3 0,932 RGS16 2,316 ZC3H12A 1,38 DNAJB1 0,54
74 HSP90B1 0,523 BMP2K* 0,935 ZFP36L1 2,331 NFKBIA 1,435 IGLL1 0,545
75 KLHDC5* 0,525 CTSH 0,935 TRIB3 2,354 RGS16 1,437 TFDP1* 0,558
76 RP9* 0,526 PLEKHO1 0,94 IL21R* 2,373 GADD45B 1,481 PSPC1* 0,56
77 PEA15 0,528 RPS6KA1 0,956 KLF6* 2,383 MIR155HG* 1,498 ANKRD33B* 0,562
78 MT1X 0,534 DUSP22 0,963 PHACTR1 2,423 LINC00158* 1,525 CREBZF 0,565
79 MAN1A1 0,539 IFIH1 0,991 SESN2* 2,446 PTGER4 1,563 IRF4 0,575
80 DNAJB1 0,543 OLFML2A 0,994 TNFAIP3 2,612 DTX3L* 1,58 C8orf12* 0,579
81 SOGA1* 0,554 HLA-DQB1 0,994 CD1C 2,662 CXCL10 1,616 FNBP1 0,617
82 CENPV* 0,555 COL1A1* 1,003 PLEK 2,716 TNFAIP3 1,636 ANXA7 0,641
83 ICAM1 0,567 ICAM1 1,006 FAM46C* 2,926 MX1 1,638 MT1X 0,67
84 CD58 0,568 NFKB2 1,009 CD83 2,973 STAT1 1,659 BATF 0,702
85 NCOR2 0,578 NEIL2* 1,021 DDIT3 2,977 BIRC3 1,66 CALR 0,703
86 SNHG12* 0,585 FNBP1 1,041 DUSP2 3,004 EGR2 1,69 HLA-DQA1* 0,706
87 SLC23A2 0,586 BATF 1,061 SQSTM1 3,036 NFKBIE 1,765 OLFML2A 0,714
88 OLFML2A 0,588 CCDC28B 1,066 PHLDA1 3,048 IFIT5 1,913 UMODL1* 0,716
89 LRRFIP1 0,59 MAN1A1 1,082 BHLHE40 3,141 BCL2A1 1,942 HLA-DQB1 0,723
90 DENND4A 0,599 CUX2 1,089 SLAMF7* 3,147 IRF1 1,965 IKBKE 0,723
91 IGLL1 0,614 HLA-DQA1* 1,092 CCR7 3,572 SLC30A1 1,969 NEIL2* 0,726
92 OVOS2* 0,63 DENND4A 1,101 NA* 3,693 IFIT3* 1,973 RILPL2* 0,779
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Table 3 Most prominent altered genes after in vitro interventions of human transformed germinal centre B cells
investigated in gene expression profiles of primary samples of aggressive Non-Hodgkin Lymphoma (Continued)
93 C1orf63 0,649 HLA-DPA1 1,105 LINC00158* 3,798 IRF4 2,167 MAN1A1 0,781
94 EIF5B 0,681 RILPL2* 1,117 LY9* 4,131 IFIT1 2,186 CREM 0,795
95 RUNX3 0,702 DOCK10 1,202 EGR1* 4,232 CMPK2* 2,253 HLA-DPA1 0,816
96 NA 0,704 BTN2A2 1,254 BCL2A1 4,295 BATF 2,3 ACTR3* 0,833
97 HLA-DQB1 0,726 NA 1,262 EGR2 4,518 CD83 2,705 CD58 0,834
98 HLA-DQA1 0,731 ELL2* 1,467 SGK1 4,84 SGK1 2,798 NA 0,952
99 TCOF1 0,744 CD58 1,62 DUSP5 5,011 ICAM1 2,918 LINC00158* 0,954
100 ELL2* 0,747 LINC00158* 1,793 RGS1 5,476 IRF9 3,155 IFIT3* 1,051
Two independent patients cohort were tested. The gene expression from 219 primary lymphoma samples described by Hummel et al. (MMML-1 cohort) and 99
primary lymphoma samples published by Dave et al. (LLMPP-cohort) were compared to global gene expression changes described within the text [20,21]. The
deviation from the TOP100 LIMMA gene lists from in vitro interventions is determined by the absence of hybridization probes on the microarrays used for
lymphoma gene expression description. In addition multiple hybridization probes for one gene were condensed into a single event.
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http://www.biosignaling.com/content/10/1/43lymphomas are depicted characterized by a high expres-
sion of genes reflecting an increased expression of genes
building the αIgM gene module. Lymphoma cases repre-
sented on the left side of the heatmap are characterized by
gene expression comparable to unstimulated cells in vitro
(BL2). Note that the genes are coherently expressed across
lymphoma. There is a continuous gradient when lymph-
omas are arranged by increasing expression of genes from
the αIgM gene module. Thus, the global gene expression
change is absent or present in individual lymphomasFigure 4 Changes in global gene expression separates Burkitt lympho
TOP100 most prominent responding genes upon stimulation of BL2 with α
panel: 220 lymphoma cases [20]; right panel: 99 lymphoma cases [21]. NHL
αIgM affected genes in BL2 cells. The Heatmaps display the expression of t
colour bar above the heatmaps marks mBL in red, non-mBL in green and i
of samples to ABC/GCB DLBCL subgroups and the presence of an IG-MYC t
map (see legend for colour coding). Relative gene expression is encoded w
microarrays were used for the whole genome expression analyses of cell p
plus2.0), the list of TOP100 genes had to be adapted to be able to transfer
Methods section and Supplementary material for additional details).(Figure 4A). Most BLs are characterized by the absence or
low expression of the αIgM gene module and thus lack
corresponding pathway activities. This is also observed in
the LLMPP cohort (Figure 4B) [21]. Therefore, it is reason-
able to believe that individual lymphomas with a high gene
module expression are characterized by a stronger activa-
tion of oncogenic pathways than those with a low expres-
sion of same genes. Therefore human transformed GC B
cells (BL2) can be defined as a suitable in vitro model used
as surrogate for pathway activity.ma and diffuse large B cell lymphoma. The expression of the
IgM F(ab)2 fragments was investigated in primary lymphoma. Left
cases were ordered from left to right according to their expression of
arget genes (columns) across lymphoma samples (rows). The lower
ntermediate lymphoma in yellow (molecular diagnosis). The affiliation
ranslocation is encoded in the middle and upper bar on top of the
ith yellow (high expression) and blue (low expression). As different
erturbation and patient samples (Affymetrix HGU-133A and HGU133
the resulting genes to patient data (see also Table 3, Material and
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discriminate individual DLBCL
As BLs are discriminated on the molecular level from other
lymphomas as shown by us and Dave et al. [20,21], we next
focused on gene expression changes mediated by BAFF,
LPS, IL21 or CD40L in vitro in comparison to αIgM in in-
dividual DLBCLs (Figure 5). DLBCL cases were arranged
according to the activity of the αIgM gene module. The
genes are coherently expressed across lymphomas and
there is a continuous gradient when lymphomas are
arranged by their increase in the expression of genes from
the gene module of IL21 or CD40L in a comparable way as
αIgM. This holds also true for the BAFF/LPS driven gene
modules within the MMML1 cohort. This highly signifi-
cant difference is observed by comparing lymphoma
cases from the MMML-1 cohort by describing three
main groups with low, intermediate and high module ac-
tivation using corresponding box plots (Additional file 23:
Figure S2). The differences are highly significant with
respective p-values: p < 2.2e-16 / p = 1.669e-10 (αIgM),
p < 2.2e-16 / p = 9.1e-07 (CD40L), p < 2.2e-16 / p = 5.9e-08
(IL21), p < 2.2e-16 / p = 2.614e-05 (BAFF), p < 2.2e-16 /
p = 1.6e-4 (LPS) in MMML or LLMPP samples.
The comparison of our data with the recently defined
groups of ABC-like or GCB-like DLBCLs reveals no dir-
ect association with one of the gene modules presented
here (Figure 5, labels on top of the heatmaps) [22]. At
the same time, DLBCLs with a MYC translocation are
characterized by low gene module activation. Lymph-
omas carrying a MYC break are absent in those patients
characterized by a higher activation of gene modules.
Importantly, DLBCLs characterized by a very high gene
module activation show evidence for the expression of
genes involved in cell-cell communication or immune
responses as well as negative feedback regulatory loops
as RGSs and DUSPs [56,57]. A different expression of
genes involved in cell-cell communication or immune
responses in GCB-like DLBCLs may suggest a different
capacity of lymphoma cells to evade immune responses
of the host. Furthermore, the activation of negative
feedback loops suggests, that although gene modules
are typical for acutely activated genes, their outcome
seems to be a balance of activating and suppressing
signals. These signals imply strong oncogenic pathway
activation but also damped cellular activity due to di-
verse negative feedback reactions or still present tumor
suppressor activities.
Highly activated CD58 is part of gene expression
changes defined by four stimuli and may present an
important marker for DLBCLs. This is in line with re-
cent observations from transcriptome sequencing of
DLBCLs. A significant number of DLBCL mutations
were identified affecting the CD58 gene [58]. It was
suggested that these mutations might play a role inthe escape from immune-surveillance of these lymph-
omas [58,59]. Therefore, it is tempting to speculate
that DLBCL with high CD58 expression would be less
efficient in immune escape compared to those with
reduced CD58 expression or loss of expression due to
genetic alterations in this gene. This is also in agree-
ment with our GO analysis, suggesting strong effects
on antigen presentation. This is further supported by
the expression changes of HLA molecules.
The DUSP family is a set of molecular control mole-
cules which modulate MAPK signalling. DUSPs are
affected by all stimuli and also present in the gene mod-
ules identified. Their role, either as phosphatases or scaf-
fold proteins, remains to be elucidated as they are
involved in defining the magnitude of pathway activity
in DLBCLs. The same holds true for the SLAMFs. They
play an essential and non-redundant role in the control
of humoral immune responses. It would be interesting
to investigate whether their expression is functionally
linked to the recently observed aberrations in CD58 or
ß2M in DLBCLs that might be involved in differences in
the capacity to escape host immune responses [41,58].
RGS1 gene expression is characteristic for GCB-like
DLBCLs [20]. It is part of the αIgM driven gene module.
RGS1 affects chemokine receptor signalling contributing
to its desensitization [56]. However, the role of chemo-
kine signalling in lymphomagenesis is not yet fully
understood. There are reports suggesting that NHLs ex-
press functional chemokine receptors. These, at least in
part, dictate tissue localisation and perhaps metastatic
potential. However, other reports show that DLBCLs are
less sensitive for the CXCR4 ligands CXCL12 and 13
[60,61]. The gene expression changes described above
for CCR7 and CXCL10 suggest a strong difference of
DLBCLs regarding migratory potential and recruitment
capacity of cells of the microenvironment but also spe-
cific chemokine responsiveness. Because CCR7 and
CXCL10 play a pivotal role in the homing of tumour
cells as shown by its role in chronic lymphatic leukemia
or Hodgkin lymphoma this has to be investigated in the
future in more detail. It would be interesting to estimate
its role in differences in lymphoma dissemination in re-
lation to the clinical outcome [43,44,62,63].
Strikingly, gene modules of IL21, CD40L or αIgM,
even though derived from different data sets, almost per-
fectly discriminate individual DLBCL. The higher a
lymphoma expresses direct αIgM targets the higher it
also expresses IL21 or CD40L inducible genes and vice
versa. While some explanations can be taken into ac-
count, we would favour the following: the aperture of
global gene expression changes obtained by computa-
tional biology is condensing pathway activities and sup-
ports the idea of parallel or equivalent functioning
oncogenic activities in individual DLBCLs.
Figure 5 Individual diffuse large B cell lymphomas are characterized by a specific activation of gene modules. The TOP100 most
prominent responding genes upon stimulation of BL2 with αIgM, CD40L, IL21, LPS and BAFF (see also Table 1) were investigated for their
expression in the gene expression profiles of two distinct datasets of primary lymphoma. (A) left panel: 175 DLBCLs [20]; right panel: 99 DLBCL
cases [21]. DLBCL cases were ordered from left to right according to the similarity of gene expression to the stimulated status of BL2 cells. The
Heatmaps display the expression of target genes (columns) across lymphoma samples (rows). The colour bar above the heatmaps marks mBL in
red, non-mBL in green and intermediate lymphoma in yellow. The affiliation of samples to ABC/GCB DLBCL subgroups and the presence of an
IG-MYC translocation in encoded in a bar on top of the map (see legend for colour coding). Relative gene expression is encoded with yellow (high
expression) and blue (low expression). Additional details on statistical significant differences are summarized within Additional file 7: Figure S1.
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mechanisms driving differential expression of gene mod-
ules. In order to define potential key molecular determi-
nants, signalling pathways involved in the regulation of a
set of genes affected by in vitro interventions were spe-
cially inhibited using chemical inhibitors.
B cell receptor regulated genes are dominantly affected
by ERK1/2 and PI3K activation
Pathway activation by IL21, CD40L, αIgM, BAFF or LPS
reflects qualitative and quantitative differences mediated
by the activation of the following pathways: Jak/STAT,
NF-кB, JNK1/2, p38a, PI3K, Erk1/2 and Ca2+ influx by
immunoblotting, kinase activity measurement or flow
cytometry (Additional file 24: Figure S3). We summar-
ized the pathways activated in our model system in a
scheme on Figure 6A. αIgM treatment is associated with
Ca2+ mobilization. Furthermore Erk1/2, Akt and p38a
phosphorylation or enhanced activity of JNK is observed.
In addition, the canonical and non-canonical NFкB
pathways are activated to some extent as revealed by
IкBα degradation and p100 to p52 processing. CD40L
activates both canonical and non-canonical NF-кB at the
highest level compared to the other stimuli. In addition
a p38 phosphorylation and JNK kinase activity is
observed comparable to that of αIgM treatment. IL21
stimulation of BL2 cells is mainly associated with STAT1
and STAT3 activation as shown by tyrosine phosphoryl-
ation. A slightly reduced expression of IкBα after IL21
treatment is observed, suggesting an activation of the ca-
nonical NF-кB. Thus, the perfect discrimination of indi-
vidual DLBCLs by three different gene modules suggest
different magnitudes of simultaneous oncogenic activ-
ities mediated by for example Jak/STAT, NF-кB, MAPK
(MAPK8/JNK1, MAPK14/p38a, MAP2K1/2), PI3K and
Ca2+ mediated responses.
Of the stimuli used in this study, αIgM treatment had
the strongest effects on gene expression in vitro and
was capable to activate a wide range of signalling path-
ways. Therefore, we wanted to further explore pathways
involved in the observed differences between individual
lymphomas characterized by specific gene module acti-
vation. We used chemical kinase inhibitors to identify
the pathways involved in the regulation of gene mod-
ules in response to stimulation. The utilized inhibitors
are summarized in a scheme in Figure 6B showing the
hierarchy of kinases in a prior knowledge scheme [2].
The following kinases were considered: MAPK includ-
ing p38, JNK1/2 or MAP2K1/2 affecting Erk1/2 activa-
tion or MAP3K7/TAK1 potentially involved in NF-κB
and MAPK signalling. Furthermore, we investigated
IKK2 as part of NF-кB signalling and PI3K as it is
involved in numerous pathways activated through
αIgM, including Akt.BL2 cell were preincubated for 3 hrs with specific inhi-
bitors and then stimulated by αIgM for additional 3 hrs
in the presence of respective inhibitors.
The expression of SGK1, PYGO1, SLAMF3, DUSP10,
EGR2, ID3, CCR7, DUSP2, SLAMF6, BCL6, MYC, LEF1,
BCL9, IRF4 and RGS1, DUSP5, SLAMF7 after αIgM
treatment was investigated in the absence or presence of
the above mentioned kinase inhibitors. Three main groups
of regulatory interactions are observed:
Within the first group are genes affected by U0126
interrupting the activity of MAP2K1/2 and Ly294002
inhibiting PI3K. Within this group are SGK1, PYGO1,
SLAMF3/7 and DUSP10 or BCL6, (Figure 6C, D, E and
Additional file 25: Figure S4 A, B, D). This suggests a
central role for Erk1/2 and PI3K. Within the second
group are genes, dominantly affected by U0126 but not
Ly294002. The expression of EGR2, ID3, CCR7, DUSP2/
5 or SLAMF6 and RGS1 is mostly regulated by Erk1/2
(Figure 6F, G, H, I, J, N and Additional file 25: Figure S4 E).
In addition, a third group of genes including MYC, LEF1
as well as BCL9 is affected by Ly294002 but not U0126
(Figure 6K, L and Additional file 25: Figure S4C).
Interestingly, IRF4 is the only gene which αIgM affected
gene expression is regulated through TAK1/IKK2/p38 (cor-
respondingly 5Z-7-oxozeaenol / ACHP / SB203580) with-
out Erk1/2 or PI3K involvement (Figure 6M).
In addition, αIgM mediated activation of SGK1 is
affected by TAK1 inhibition (Figure 6C), whereas for ex-
ample CCR7 activation is regulated through TAK1 and
JNK (Figure 6J). Furthermore, for SGK1, ID3, CCR7 or
SLAMF6, the effect of the TAK-inhibitor is not accom-
panied by a comparable IKK2 inhibition. Whereas for
CCR7 and ID3 the known signalling cascade TAK1-JNK
can be proposed, for SGK1 either a more direct TAK1
effect or a PI3K-TAK1-Erk1/2 cascade has to be taken
into account (Figure 6C, G, H). Whereas the expression
of PYGO1 is affected by the well-known TAK1-IKK2
cascade (Figure 6D, I) for SLAMF6 and IRF4 also the
TAK1-p38 cascade seems to play a role (Figure 6J, M).
αIgM mediated MYC inhibition is reversed by the PI3K
inhibitor Ly294002. This demonstrates an involvement of
PI3K signalling to inhibit aberrant MYC expression
(Figure 6K). Furthermore, an effect of JNK-, IKK2- or
PI3K inhibition on basal expression of MYC can be
observed. This supports a role of a tonic activation (basal
signalling in unstimulated BL2 cells) of PI3K, JNK and
IKK2 mediated signalling activity in regulating aberrant
“basal” MYC expression. Interestingly, a new murine
model for lymphomas has been described supporting the
view of a synergistic action of c-Myc and PI3K signalling
[64]. Furthermore, a tonic BCR signalling and PI(3) kin-
ase activity in Burkitt’s lymphoma has been recently
described by Schmitz and co-workers [65]. However, this
link between tonic PI3K signalling and MYC expression
Figure 6 Pathways involved in the regulation of a selected set of genes in response to αIgM treatment. (A) Prior knowledge scheme of
monitored pathways. Dashed lines implicate the presence of additional signalling molecules interlinking the depicted factors, solid lines reflect a
direct link. (B) hierarchical presentation of kinases affected by utilized chemical inhibitors [2]. (C-N) BL2 cell were preincubated for 3 hrs with 2 μM
SB203580 (p38), 10 μM SP600125 (JNK), 10 μM U0126 (MAP2K), 100nM 5Z-7-oxozeaenol (TAK), 7 μM ACHP (IKK2) or 10 μM Ly294002 (PI3K)
inhibitors and then stimulated by 1.3 μg/ml αIgM F(ab)2 fragments for additional 3 hrs in the presence of respective inhibitors. Cells were
harvested to isolate RNA for corresponding qRT-PCR. Expression of the following genes is shown: SGK1, PYGO1, SLAMF3, EGR2, ID3, CCR7, DUSP2,
SLAMF6, MYC, LEF1, IRF4 and RGS1. Results are presented as 2-ΔΔCT values, relative to abl housekeeper expression and compared to the
corresponding unstimulated inhibitor treated control. As RGS1 (N) expression is below detectable levels in unstimulated probes, only ΔCt values
relative to stimulated control without inhibitors were compared. One representative experiment out of three or more biological replicates is
shown. Cells were treated with DMSO (1/8) 5Z-7-oxozeaenol (2/9), ACHP (3/10), SB203580 (4/11), SP600125 (5/12), Ly294002 (6/13), U0126 (7/14)
in the absence (1–7) or presence of αIgM F(ab)2 fragments (8–14). n.e. – not expressed. Details on pathway activations as measured by
immunoblot, kinase activity and Ca2+ influx analysis are summarized in Additional file 24: Figure S3.
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in this study treatment of BL lines with BKM120, a PI(3)
kinase inhibitor in clinical trials, or rapamycin, an inhibi-
tor of the mTORC1 complex, was toxic to most BL lines
after 4 days. Therefore, their rapamycin signature has to
be taken into account for future investigations. Surpris-
ingly, IKK2 inhibition was associated with a much stron-
ger αIgM mediated suppression of MYC expression
(Figure 6K) [66]. Therefore, we observed a suppressiverole of tonic IKK2 activity onto MYC expression in BL2
cells. This sheds new light onto the regulation of the ab-
errant expression of MYC. Positive and negative signals
from PI3K, MAPK and NF-kB pathways can now be
investigated in more detail for example in order to delin-
eate differences between BLs and DLBCLs characterized
by a high Myc-index or MYC break [67].
A comparable effect of PI3K-inhibition as described
for MYC is observed also for BCL6, LEF1 and BCL9
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ever, as for MYC, the expression of BCL6 or BCL9 is
already affected to some extend by Ly294002 in un-
stimulated BL2 cells. Therefore, it is difficult to interpret
these data for BCL6 and BCL9 to the end (Additional file
25: Figure S4 B, C). We speculate that combinations of
pathways are involved in both basal and αIgM mediated
gene expression.
In Figure 7A a scheme summarizes the main effects of
kinase inhibition observed after αIgM treatment.
As already noted above, in some cases the treatment
of cells with inhibitors is associated with an enhanced
activation or inhibition of respective genes. For ex-
ample treatment of cells with Ly294002 led to a stron-
ger activation of EGR2 or CCR7 by αIgM treatment
(Figure 6E, G). Comparable effects are observed for
IKK2 inhibition for SLAMF3 and ID3, for p38 or JNK
inhibition analysing SGK1, ID3 or PYGO1 respectively
(Figure 6C, D, E, G). In Figure 7B a respective sum-
mary of main αIgM enhancing effects after inhibition
of specific kinases is shown, including effects of these
inhibitors onto the basal expression levels of analysed
genes as for example MYC or BCL9.
Overall, we found that the expression of most of the
analyzed genes affected by αIgM treatment is regulated
through Erk1/2 activation accompanied by PI3K, TAK1
and partially to lower extent by IKK2 and JNK.
Erk and PI3K signalling is exclusive to the αIgM gene
module (Additional file 24: Figure S3 D, G). TheseFigure 7 Schemes summarizing investigated kinase involvement in αI
of gene expression (A) and suppressive effects of pathway elements onto selec
the scheme (A) genes are listed and sorted according to the groups described
expression changes of BCL6, BCL9, DUSP5, DUSP10 and SLAMF7 are described wpathways are not affected by the other in vitro treat-
ments Activated NF-кB signalling seems to be less im-
portant for the αIgM gene module. However, the
analysis of CD40 mediated expression of ICAM1, CD58,
SLAMF3 or CCR7 revealed a strong involvement of
NF-кB signalling (data not shown). Our analysis sup-
ports the idea that the MAPK/Erk-pathway has a major
impact on gene expression in individual DLBCL with a
high activation of the αIgM gene module. Therefore, it is
reasonable to discuss the use of drugs targeting Erk1/2
for a subgroup of DLBCL characterized by a high activa-
tion of the αIgM driven gene module [68]. In a recent
study, a molecular interaction of Erk and CHK2 was
shown to affect DNA-damage response and apoptosis of
DLBCLs [69]. The recently described success of using
Syk or Btk inhibitors or even mTOR and PKC inhibitors
to treat DLBCL might be explained by the activity of
these signalling pathways [70-75]. We are aware of the
limitations of chemical kinase inhibitors to analyse path-
way elements. However, as comparable compounds are
developed for clinical applications, the information
drawn from studies integrating in vitro stimulations as
pathway surrogates with gene expression of individual
lymphoma patients will provide comprehensive insights
into potential targets for therapy. In the future the uti-
lized in vitro stimulations can be used in combination
with kinase inhibitors to delineate respective pathway
interactions as for example a link between TAK1 and
Erk1/2 or the different branches within PI3K signallinggM mediated gene expression. αIgM mediated activation / induction
ted genes affecting basal and αIgM mediated gene expression (B). Within
within the main text in relation to corresponding kinases. Data for gene
ithin Additional file 25: Figure S4.
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Furthermore, our data indicate that a global investiga-
tion of kinase inhibitors and their combinations would
be useful for a better understanding of gene regulation
of global gene expression changes and their integration
with patient’s data.
Conclusions
We provide an in vitro model system to investigate path-
way activations qualitatively and quantitatively. B cell
specific stimuli are used to identify gene expression
changes allowing to “switch“ gene expression from one
steady state level characteristic for BL towards that of
DLBCLs. We defined the extent to which specific signal-
ling pathways are responsible for differences in gene ex-
pression that distinguish individual DLBCL. Gene modules
of IL21, CD40L or αIgM discriminate individual DLBCL,
from each other, even though derived from different data
sets. The greater an individual lymphoma expresses αIgM
target genes, the greater it will also express IL21 or CD40L
regulated genes.
We have shown that mitogen activated protein kinase-
and phosphoinositide 3 kinase-signaling are an import-
ant part of pathway networks describing differences in
gene expression that distinguish individual DLBCL. This
observation supports recent findings about the role of
tonic and/or chronic active MAPK signalling in individ-
ual lymphoma and might therefore constitute a promis-
ing target for future therapy approaches. Although the
discrimination of individual DLBCL by three different
gene modules suggest different magnitudes of parallel or
equivalent oncogenic activities mediated by Jak/STAT,
NF-кB, MAPK. Therefore, transformed human germinal
centre B cells can be used to test new compounds and
their influence on the respective pathways in DLBCLs. A
useful tool to test for individual treatment strategies is
offered, which is independent from heterogeneous
lymphoma associated mutations know from DLBCLs.
Materials and methods
Cell culture and stimulation
BL2 cells were cultivated as described previously at cell
densities between 2 × 105 and 1 × 106 cells/ml [63]. For
stimulation studies, cells were cultured in cell culture
medium supplemented with 10 mM HEPES at 1 × 106
cells/ml and incubated with indicated reagents for up to
9 hrs. To crosslink the BCR, BL2 cells were cultured in
the presence of 1.3 μg/ml goat αIgM F(ab)2 fragments
(Jackson Immunity). Recombinant human sCD40L
(AutogenBioclear), human BAFF (R&D Systems) and re-
combinant human IL21 (Peprotech) were used at a con-
centration of 200 ng/ml, 100 ng/ml and 100 ng/ml
respectively. LPS (E. coli strain 055:B5, Sigma) was
added to the cells at a concentration of 1 μM.Cells were harvested using corresponding inhibitors of
phosphatases and proteases and RNA was isolated using
the RNeasy Plus Mini Kit (Qiagen).
Immunoblot, Calcium Measurement, JNK Immuno-
complex kinase assays and qRT-PCR analysis are sum-
marized within supplemental Material and Methods.
Gene expression analysis
For gene expression analysis RNA was isolated with
RNeasy Plus Mini Kit (Qiagen) according to the manu-
facturer’s instructions. For real time PCR analysis RNA
was reverse transcribed using SuperScript II Reverse
Transcriptase (Invitrogen) and random hexamer primers
(IBA BioTAGnology). cDNA samples were further ana-
lysed by SYBR Green-based real-time PCR using the
7900HT Fast Real-Time PCR System (Applied Biosys-
tems) (additional details for used primers within the
Additional file 26: Table S17). For whole genome micor-
arrays RNA was labelled for microarray hybridization
using Affymetrix GeneChipW IVT Labelling Kit (Affyme-
trix). Fragmentation and hybridization of labelled anti
sense RNA on Human Genome U133A 2.0 plus Arrays
(Affymetrix) was performed according to manufacturer’s
recommendations by the Kompetenzzentrum für Fluores-
zente Bioanalytik. Rawdata have been uploaded to GEO
and can be assessed using GSE42660. Gene expression
values were obtained by first correcting for the back-
ground and normalizing on probe level using the vari-
ance stabilization method by Huber and colleagues [55].
The normalized probe intensities were summarized into
gene expression levels by using an additive model fitted
by the median polish procedure [76,77]. If there was
more than one probeset per gene, we kept the probeset
best responding. This was done by looking at the fold
changes between control and stimulation, the probeset
with the highest fold change was kept. Additional details
for Biostatistics are summarized within supplemental Ma-
terial and Methods. Ethical approval for gene expression
studies on human lymphoma material was granted and
described in detail by Hummel and colleagues [20] as
well as Dave and colleagues [21]. These studies were con-
ducted in compliance with the Declaration of Helsinki.
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